Pathobiology of pulmonary hypertension - The role of platelets and thrombosis

被引:131
作者
Herve, P
Humbert, M
Sitbon, O
Parent, F
Nunes, H
Legal, C
Garcia, G
Simonneau, G
机构
[1] Univ Paris Sud, Hop Marie Lannelongue, Clamart, France
[2] Hop Antoine Beclere, Ctr Malad Vasc Pulm, Serv Pneumol & Reanimat Resp, Clamart, France
关键词
D O I
10.1016/S0272-5231(05)70283-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Thrombotic lesions are among the most frequent histopathological lesions seen in pulmonary arterial hypertension. However, with the rare exceptions of pulmonary arterial hypertension associated with antiphospholipid antibodies, or genetic platelet dysfunction, or inherited deficiencies of antithrombotic pathways, these thrombotic lesions are secondary in most cases of primary or secondary pulmonary arterial hypertension. Pulmonary arterial hypertension is associated not only with thrombotic lesions but also with persistent vasoconstriction and structural remodeling of pulmonary arteries. By interacting with the pulmonary arterial wall, activated platelets may contribute to the functional and structural alterations of pulmonary vessels through the release of various vasoactive mediators and growth factors.
引用
收藏
页码:451 / +
页数:9
相关论文
共 52 条
[31]   HETEROGENEITY OF PATHOLOGIC LESIONS IN FAMILIAL PRIMARY PULMONARY-HYPERTENSION [J].
LOYD, JE ;
ATKINSON, JB ;
PIETRA, GG ;
VIRMANI, R ;
NEWMAN, JH .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 138 (04) :952-957
[32]   5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension [J].
MacLean, MR ;
Herve, P ;
Eddahibi, S ;
Adnot, S .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (02) :161-168
[33]   Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines [J].
Maher, TJ ;
Ulus, IH ;
Wurtman, RJ .
LANCET, 1999, 353 (9146) :38-38
[34]   Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7 [J].
Morse, JH ;
Barst, RJ ;
Fotino, M ;
Zhang, Y ;
Flaster, E ;
Gharavi, AE ;
Fritzler, MJ ;
Dominguez, M ;
AnglesCano, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (01) :274-278
[35]   CHRONIC MAJOR-VESSEL THROMBOEMBOLIC PULMONARY-HYPERTENSION [J].
MOSER, KM ;
AUGER, WR ;
FEDULLO, PF .
CIRCULATION, 1990, 81 (06) :1735-1743
[36]   DO PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION DEVELOP EXTENSIVE CENTRAL THROMBI [J].
MOSER, KM ;
FEDULLO, PF ;
FINKBEINER, WE ;
GOLDEN, J .
CIRCULATION, 1995, 91 (03) :741-745
[37]   ENDOGENOUS FIBRINOLYTIC SYSTEM IN CHRONIC LARGE-VESSEL THROMBOEMBOLIC PULMONARY-HYPERTENSION [J].
OLMAN, MA ;
MARSH, JJ ;
LANG, IM ;
MOSER, KM ;
BINDER, BR ;
SCHLEEF, RR .
CIRCULATION, 1992, 86 (04) :1241-1248
[38]  
PIETRA GG, 1997, PRIMARY PULMONARY HY
[39]   THE EFFECT OF HIGH-DOSES OF CALCIUM-CHANNEL BLOCKERS ON SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION [J].
RICH, S ;
KAUFMANN, E ;
LEVY, PS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :76-81
[40]   PULMONARY-HYPERTENSION ASSOCIATED WITH LONG-STANDING THROMBOCYTOSIS [J].
ROSTAGNO, C ;
PRISCO, D ;
ABBATE, R ;
POGGESI, L .
CHEST, 1991, 99 (05) :1303-1305